Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 776

The DOI matches its Crossref record.

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

Open access
Tan, Chen S, Koralnik, Igor J·2010·The Lancet Neurology
DOI 10.1016/s1474-4422(10)70040-5
Open this paper in CoChat — free account

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare but often fatal brain disease caused by the reactivation of the polyomavirus JC (JCV). Characteristics of PML have expanded considerably since the onset of the HIV epidemic with the advent of combination antiretroviral therapy (cART), and the development of immune reconstitution inflammatory syndrome in PML lesions (PML-IRIS). Recently, the monoclonal antibodies natalizumab, efalizumab and rituximab used for treatment of multiple sclerosis, psoriasis, hematologic malignancies, Crohn’s and rheumatic diseases, have been associated with PML. In addition, JCV can also infect neurons, leading to novel neurological disorders JC virus granule cell neuronopathy (JCV GCN) and JC virus encephalopathy (JCVE), and it may also cause meningitis. The newly observed features of PML, the increasingly diverse populations at risk, and the recently discovered grey matter involvement by JCV invite us to reappraise the expanded pathogenesis of this virus in the central nervous system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(10)70040-5

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 112

  1. Koralnik, 2006, Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?, Ann Neurol, 60, 162, 10.1002/ana.20933 · DOI · Paper page
  2. Eng, 2006, Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population, Neurology, 67, 884, 10.1212/01.wnl.0000233918.21986.9c · doi:10.1212/01.wnl.0000233918.21986.9c
  3. Holman, 1991, Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data, Neurology, 41, 1733, 10.1212/WNL.41.11.1733 · DOI
  4. Koralnik, 2004, Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14–2004. A 66-year-old man with progressive neurologic deficits, N Engl J Med, 350, 1882, 10.1056/NEJMcpc030038 · DOI
  5. Molloy, 2009, Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases, Arthritis Rheum, 60, 3761, 10.1002/art.24966 · doi:10.1002/art.24966
  6. Van Assche, 2005, Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease, N Engl J Med, 353, 362, 10.1056/NEJMoa051586 · DOI · Paper page
  7. Langer-Gould, 2005, Progressive multifocal leukoencephalopathy in a patient treated with natalizumab, N Engl J Med, 353, 375, 10.1056/NEJMoa051847 · DOI · Paper page
  8. Kleinschmidt-DeMasters, 2005, Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis, N Engl J Med, 353, 369, 10.1056/NEJMoa051782 · DOI · Paper page
  9. Carson, 2009, Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project, Blood, 113, 4834, 10.1182/blood-2008-10-186999 · DOI · Paper page
  10. Korman, 2009, Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists, Arch Dermatol, 145, 937, 10.1001/archdermatol.2009.175 · DOI
  11. Komagome, 2002, Oligosaccharides as receptors for JC virus, J Virol, 76, 12992, 10.1128/JVI.76.24.12992-13000.2002 · doi:10.1128/jvi.76.24.12992-13000.2002
  12. Elphick, 2004, The human polyomavirus, JCV, uses serotonin receptors to infect cells, Science, 306, 1380, 10.1126/science.1103492 · DOI · Paper page
  13. Gray, 2001, Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells, Mol Pharmacol, 60, 1020, 10.1124/mol.60.5.1020 · DOI
  14. Fonseca, 2001, Distribution of serotonin 2A, 2C and 3 receptor mRNA in spinal cord and medulla oblongata, Brain Res Mol Brain Res, 89, 11, 10.1016/S0169-328X(01)00049-3 · DOI
  15. Cohen, 1999, Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization, J Cereb Blood Flow Metab, 19, 908, 10.1097/00004647-199908000-00010 · DOI
  16. Atwood, 1992, Interaction of the human polyomavirus, JCV, with human B-lymphocytes, Virology, 190, 716, 10.1016/0042-6822(92)90909-9 · DOI
  17. Monaco, 1998, Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection, J Virol, 72, 9918, 10.1128/JVI.72.12.9918-9923.1998 · doi:10.1128/jvi.72.12.9918-9923.1998
  18. Tan, 2009, Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation, J Infect Dis, 199, 881, 10.1086/597117 · doi:10.1086/597117
  19. Jensen, 2001, A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region, J Neurovirol, 7, 280, 10.1080/13550280152537102 · doi:10.1080/13550280152537102
  20. Frisque, 1984, Human polyomavirus JC virus genome, J Virol, 51, 458, 10.1128/JVI.51.2.458-469.1984 · DOI · Paper page
  21. Monaco, 1996, JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency, J Virol, 70, 7004, 10.1128/JVI.70.10.7004-7012.1996 · DOI · Paper page
  22. Randhawa, 2005, Quantitation of DNA of polyomaviruses BK and JC in human kidneys, J Infect Dis, 192, 504, 10.1086/431522 · doi:10.1086/431522
  23. Markowitz, 1993, Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects, J Infect Dis, 167, 13, 10.1093/infdis/167.1.13 · doi:10.1093/infdis/167.1.13
  24. Kitamura, 1990, High incidence of urinary JC virus excretion in nonimmunosuppressed older patients, J Infect Dis, 161, 1128, 10.1093/infdis/161.6.1128 · doi:10.1093/infdis/161.6.1128
  25. Koralnik, 1999, JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy, Neurology, 52, 253, 10.1212/WNL.52.2.253 · DOI · Paper page
  26. Yogo, 1990, Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals, J Virol, 64, 3139, 10.1128/JVI.64.6.3139-3143.1990 · doi:10.1128/jvi.64.6.3139-3143.1990
  27. Pfister, 2001, JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy, J Virol, 75, 5672, 10.1128/JVI.75.12.5672-5676.2001 · doi:10.1128/jvi.75.12.5672-5676.2001
  28. Padgett, 1973, Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy, J Infect Dis, 127, 467, 10.1093/infdis/127.4.467 · DOI · Paper page
  29. Knowles, 2003, Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40, J Med Virol, 71, 115, 10.1002/jmv.10450 · DOI · Paper page
  30. Weber, 1997, Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy, J Infect Dis, 176, 250, 10.1086/514032 · doi:10.1086/514032
  31. Engels, 2005, Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma, Int J Cancer, 117, 1013, 10.1002/ijc.21277 · doi:10.1002/ijc.21277
  32. Stolt, 2003, Seroepidemiology of the human polyomaviruses, J Gen Virol, 84, 1499, 10.1099/vir.0.18842-0 · doi:10.1099/vir.0.18842-0
  33. Egli, 2009, Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors, J Infect Dis, 199, 837, 10.1086/597126 · DOI · Paper page
  34. Hamilton, 2000, Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus, J Clin Microbiol, 38, 105, 10.1128/JCM.38.1.105-109.2000 · doi:10.1128/jcm.38.1.105-109.2000
  35. Weber, 2001, Cellular and humoral immune response in progressive multifocal leukoencephalopathy, Ann Neurol, 49, 636, 10.1002/ana.1004 · doi:10.1002/ana.1004
  36. Giudici, 2000, Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response, Clin Infect Dis, 30, 95, 10.1086/313598 · doi:10.1086/313598
  37. Gasnault, 2003, Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy, AIDS, 17, 1443, 10.1097/00002030-200307040-00004 · DOI
  38. Koralnik, 2001, JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy, J Virol, 75, 3483, 10.1128/JVI.75.7.3483-3487.2001 · DOI
  39. Du Pasquier, 2003, Low frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1(p36) in patients with proven or possible progressive multifocal leukoencephalopathy, J Virol, 77, 11918, 10.1128/JVI.77.22.11918-11926.2003 · DOI
  40. Du Pasquier, 2004, A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy, Brain, 127, 1970, 10.1093/brain/awh215 · DOI · Paper page
  41. Du Pasquier, 2004, Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals, J Virol, 78, 10206, 10.1128/JVI.78.18.10206-10210.2004 · doi:10.1128/jvi.78.18.10206-10210.2004
  42. Chen, 2008, BKV and JCV large T antigen-specific CD8 T cell response in HLA A*0201 kidney transplant recipients with polyomavirus nephropathy and patients with progressive multifocal leukoencephalopathy, J Clin Virol, 42, 198, 10.1016/j.jcv.2008.01.005 · DOI
  43. Koralnik, 2002, Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope, J Immunol, 168, 499, 10.4049/jimmunol.168.1.499 · DOI
  44. Lima, 2007, Frequency and phenotype of JC virus-specific CD8+ T lymphocytes in the peripheral blood of patients with progressive multifocal leukoencephalopathy, J Virol, 81, 3361, 10.1128/JVI.01809-06 · DOI
  45. Wuthrich, 2006, Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: co-localization of CD8 T cells with JCV-infected glial cells, J Neurovirol, 12, 116, 10.1080/13550280600716604 · DOI
  46. Bernal-Cano, 2007, Spinal cord lesions of progressive multifocal leukoencephalopathy in an acquired immunodeficiency syndrome patient, J Neurovirol, 13, 474, 10.1080/13550280701469178 · doi:10.1080/13550280701469178
  47. Lima, 2006, Seizures and their outcome in progressive multifocal leukoencephalopathy, Neurology, 66, 262, 10.1212/01.wnl.0000194227.16696.11 · DOI
  48. Gheuens, 2009, Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression, J Neurol Neurosurg Psychiatry
  49. Whiteman, 1993, Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation, Radiology, 187, 233, 10.1148/radiology.187.1.8451420 · doi:10.1148/radiology.187.1.8451420
  50. Cinque, 2003, The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology, J Neurovirol, 9, 88, 10.1080/13550280390195298 · DOI
  51. Gasnault, 2001, Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring, J Neurovirol, 7, 375, 10.1080/13550280152537274 · doi:10.1080/13550280152537274
  52. De Luca, 2001, Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study, J Neurovirol, 7, 364, 10.1080/13550280152537256 · doi:10.1080/13550280152537256
  53. De Luca, 2008, Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis, AIDS, 22, 1759, 10.1097/QAD.0b013e32830a5043 · DOI · Paper page
  54. Marra, 2002, A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS, AIDS, 16, 1791, 10.1097/00002030-200209060-00012 · doi:10.1097/00002030-200209060-00012
  55. Hou, 1998, The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line, J Neurovirol, 4, 451, 10.3109/13550289809114545 · doi:10.3109/13550289809114545
  56. Aksamit, 2001, Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside, J Neurovirol, 7, 386, 10.1080/13550280152537292 · doi:10.1080/13550280152537292
  57. Hall, 1998, Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team, N Engl J Med, 338, 1345, 10.1056/NEJM199805073381903 · DOI · Paper page
  58. De Luca, 1999, Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy, Clin Infect Dis, 28, 624, 10.1086/515153 · doi:10.1086/515153
  59. Verma, 2007, Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera, J Infect Dis, 196, 709, 10.1086/520514 · doi:10.1086/520514
  60. Cettomai, 2009, Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy, Arch Neurol, 66, 255, 10.1001/archneurol.2008.557 · DOI
  61. Marzocchetti, 2009, Determinants of survival in progressive multifocal leukoencephalopathy, Neurology, 73, 1551, 10.1212/WNL.0b013e3181c0d4a1 · DOI · Paper page
  62. Brickelmaier, 2009, Identification and characterization of mefloquine efficacy against JC virus in vitro, Antimicrob Agents Chemother, 53, 1840, 10.1128/AAC.01614-08 · DOI · Paper page
  63. Marzocchetti, 2009, Efficient in vitro expansion of JC virus-specific CD8 T-cell responses by JCV peptide-stimulated dendritic cells from patients with progressive multifocal leukoencephalopathy, Virology, 383, 173, 10.1016/j.virol.2008.10.046 · doi:10.1016/j.virol.2008.10.046
  64. Berger, 1998, Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy, Ann Neurol, 44, 341, 10.1002/ana.410440309 · doi:10.1002/ana.410440309
  65. Thurnher, 2001, Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy, AJNR Am J Neuroradiol, 22, 977
  66. Taoufik, 1998, Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy, J Infect Dis, 178, 1816, 10.1086/314496 · DOI
  67. Yiannoutsos, 1999, Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy, Ann Neurol, 45, 816, 10.1002/1531-8249(199906)45:6<816::AID-ANA21>3.0.CO;2-W · doi:10.1002/1531-8249(199906)45:6<816::aid-ana21>3.0.co;2-w
  68. Berger, 1998, Progressive multifocal leukoencephalopathy in patients with HIV infection, J Neurovirol, 4, 59, 10.3109/13550289809113482 · doi:10.3109/13550289809113482
  69. Antinori, 2003, Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA), J Neurovirol, 9, 47, 10.1080/13550280390195388 · doi:10.1080/13550280390195388
  70. Khanna, 2009, Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study, Clin Infect Dis, 48, 1459, 10.1086/598335 · DOI
  71. Engsig, 2009, Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study, J Infect Dis, 199, 77, 10.1086/595299 · DOI · Paper page
  72. Lima MA, Bernal-Cano F, Clifford DB, Gandhi R, Koralnik IJ. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry (in press).
  73. Murdoch, 2007, Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options, AIDS Res Ther, 4, 9, 10.1186/1742-6405-4-9 · DOI · Paper page
  74. Shelburne, 2005, Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy, AIDS, 19, 399, 10.1097/01.aids.0000161769.06158.8a · DOI · Paper page
  75. Lipman, 2006, Immune reconstitution inflammatory syndrome in HIV, Curr Opin Infect Dis, 19, 20, 10.1097/01.qco.0000200543.80712.01 · DOI
  76. Cinque, 2009, Progressive multifocal leukoencephalopathy in HIV-1 infection, Lancet Infect Dis, 9, 625, 10.1016/S1473-3099(09)70226-9 · DOI · Paper page
  77. Tan, 2009, PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids, Neurology, 72, 1458, 10.1212/01.wnl.0000343510.08643.74 · doi:10.1212/01.wnl.0000343510.08643.74
  78. Du Pasquier, 2003, Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?, J Neurovirol, 9, 25, 10.1080/13550280390195315 · doi:10.1080/13550280390195315
  79. Vendrely, 2005, Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy, Acta Neuropathol, 109, 449, 10.1007/s00401-005-0983-y · DOI · Paper page
  80. Huang, 2007, Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients, Ann Neurol, 62, 34, 10.1002/ana.21085 · doi:10.1002/ana.21085
  81. Martinez, 2006, Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder, Neurology, 67, 1692, 10.1212/01.wnl.0000242728.26433.12 · doi:10.1212/01.wnl.0000242728.26433.12
  82. Gray, 2005, Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment, J Neurovirol, 11, 16, 10.1080/13550280500511741 · DOI
  83. Linda, 2009, Progressive multifocal leukoencephalopathy after natalizumab monotherapy, N Engl J Med, 361, 1081, 10.1056/NEJMoa0810316 · DOI · Paper page
  84. Wenning, 2009, Treatment of progressive multifocal leukoencephalopathy associated with natalizumab, N Engl J Med, 361, 1075, 10.1056/NEJMoa0810257 · doi:10.1056/nejmoa0810257
  85. Schwab, 2009, Fatal progressive multifocal leukoencephalopathy associated with efalizumab therapy: insights into the role of leukointegrin aLb2 in JC virus control, Mult Scler, 15, S271
  86. Laszlo, 2006, Peripheral T-lymphocyte subsets in patients treated with rituximab-chlorambucil combination therapy for indolent NHL, Ann Hematol, 85, 813, 10.1007/s00277-006-0170-9 · doi:10.1007/s00277-006-0170-9
  87. Martin Mdel, 2009, Depletion of B lymphocytes from cerebral perivascular spaces by rituximab, Arch Neurol, 66, 1016
  88. Clifford, 2010, Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases, Lancet Neurol, 9, 438, 10.1016/S1474-4422(10)70028-4 · DOI · Paper page
  89. Yousry, 2006, Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy, N Engl J Med, 354, 924, 10.1056/NEJMoa054693 · DOI · Paper page
  90. Boster, 2009, Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study, Arch Neurol, 66, 593, 10.1001/archneurol.2009.31 · DOI
  91. Chen, 2009, Asymptomatic reactivation of JC virus in patients treated with natalizumab, N Engl J Med, 361, 1067, 10.1056/NEJMoa0904267 · doi:10.1056/nejmoa0904267
  92. Stuve, 2006, Immune surveillance in multiple sclerosis patients treated with natalizumab, Ann Neurol, 59, 743, 10.1002/ana.20858 · DOI · Paper page
  93. Stuve, 2006, Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis, Arch Neurol, 63, 1383, 10.1001/archneur.63.10.1383 · DOI · Paper page
  94. Khatri, 2009, Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function, Neurology, 72, 402, 10.1212/01.wnl.0000341766.59028.9d · DOI · Paper page
  95. Gorelik, 2009, Asymptomatic reactivation of JC virus in patients treated with natalizumab, N Engl J Med, 361, 2487, 10.1056/NEJMc0909622 · doi:10.1056/nejmc0909622
  96. Richardson, 1983, Progressive multifocal leukoencephalopathy: its pathological features, Prog Clin Biol Res, 105, 191
  97. Kuchelmeister, 1993, Cellular changes in the cerebellar granular layer in AIDS-associated PML, Neuropathol Appl Neurobiol, 19, 398, 10.1111/j.1365-2990.1993.tb00460.x · doi:10.1111/j.1365-2990.1993.tb00460.x
  98. Tagliati, 1998, Cerebellar degeneration associated with human immunodeficiency virus infection, Neurology, 50, 244, 10.1212/WNL.50.1.244 · DOI
  99. Du Pasquier, 2003, Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual, Neurology, 61, 775, 10.1212/01.WNL.0000081306.86961.33 · DOI
  100. Tyler, 2003, The uninvited guest: JC virus infection of neurons in PML, Neurology, 61, 734, 10.1212/WNL.61.6.734 · doi:10.1212/wnl.61.6.734
  101. Koralnik, 2005, JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy, Ann Neurol, 57, 576, 10.1002/ana.20431 · DOI · Paper page
  102. Otis, 2005, Images in pathology: granule cell loss in AIDS-associated progressive multifocal leukoencephalopathy, Int J Surg Pathol, 13, 360, 10.1177/106689690501300409 · doi:10.1177/106689690501300409
  103. Hecht, 2007, JC virus granule cell neuronopathy in a child with CD40 ligand deficiency, Pediatr Neurol, 36, 186, 10.1016/j.pediatrneurol.2006.10.007 · doi:10.1016/j.pediatrneurol.2006.10.007
  104. Granot, 2009, What lies beneath the tent? JC-virus cerebellar granule cell neuronopathy complicating sarcoidosis, J Clin Neurosci, 16, 1091, 10.1016/j.jocn.2008.07.091 · doi:10.1016/j.jocn.2008.07.091
  105. Wuthrich, 2009, Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy, J Neuropathol Exp Neurol, 68, 15, 10.1097/NEN.0b013e3181912570 · DOI
  106. Dang, 2006, A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene, J Gen Virol, 87, 2533, 10.1099/vir.0.81945-0 · DOI
  107. Wuthrich, 2009, Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons, Ann Neurol, 65, 742, 10.1002/ana.21619 · DOI
  108. Tallantyre, 2009, Atypical progressive multifocal leukoencephalopathy associated with an unusual JC polyomavirus mutation, Arch Neurol, 66, 1021, 10.1001/archneurol.2009.94 · doi:10.1001/archneurol.2009.94
  109. Moll, 2008, Cortical demyelination in PML and MS: similarities and differences, Neurology, 70, 336, 10.1212/01.wnl.0000284601.54436.e4 · DOI
  110. Behzad-Behbahani, 2003, BKV-DNA and JCV-DNA in CSF of patients with suspected meningitis or encephalitis, Infection, 31, 374, 10.1007/s15010-003-3078-5 · DOI
  111. Viallard, 2005, JC virus meningitis in a patient with systemic lupus erythematosus, Lupus, 14, 964, 10.1191/0961203305lu2229cr · doi:10.1191/0961203305lu2229cr
  112. Blake, 1992, JC virus associated meningoencephalitis in an immunocompetent girl, Arch Dis Child, 67, 956, 10.1136/adc.67.7.956 · doi:10.1136/adc.67.7.956

Cited by

See all 776

Metadata

Authors
Tan, C. S., & Koralnik, I. J.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2010-04
Volume
9
Issue
4
Pages
425-437
ISSN
1474-4422 (ISSN-L)
DOI
10.1016/s1474-4422(10)70040-5
OpenAlex
W2172275967
Cited by
776
References
0
FWCI
30.06
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. https://app.cochat.ai/papers/10.1016/s1474-4422(10)70040-5
The paper
Tan, C. S., & Koralnik, I. J. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(10)70040-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.